Topics

TCT 2019: Five-Year PARTNER 2A Results Support TAVR In Most Intermediate Risk Patients

06:53 EDT 3 Oct 2019 | SCRIP

<p>A new update from the PARTNER 2A trial shows transcatheter aortic valve replacement with Edwards Lifesciences' Sapien XT yields similar...

      

Related Stories

 

Original Article: TCT 2019: Five-Year PARTNER 2A Results Support TAVR In Most Intermediate Risk Patients

NEXT ARTICLE

More From BioPortfolio on "TCT 2019: Five-Year PARTNER 2A Results Support TAVR In Most Intermediate Risk Patients"

Quick Search

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...